资讯库
更紧凑的生命科学资讯库。
先搜索，再按来源或主题继续收窄。
2026年：AI在制药业从分析转向行动的关键之年
2026年：AI在制药业从分析转向行动的关键之年
FDA利益冲突问题超出顾问委员会专家范畴。
FDA利益冲突问题超出顾问委员会专家范畴。
百济神州携百悦泽登顶血癌之巅，能否再创辉煌？
百济神州携百悦泽登顶血癌之巅，能否再创辉煌？
血友病基因疗法市场遇冷，创新热潮难掩销售困境
Hemophilia gene therapies are struggling on the market, even as innovation soars The business case for hemophilia gene therapy still isn’t adding up due to persistent m...
今年FDA四大变革
4 major changes at the FDA this year The most impactful regulatory shifts for pharma in 2025 and how the industry can take advantage of new policies. Published Dec. 3,...
诺华与强生阿尔茨海默症临床试验失败，为受挫领域带来宝贵教训。
Novo, J&J Alzheimer’s clinical flops teach bruised field valuable lessons November was a tough month for highly anticipated Alzheimer’s readouts with a GLP-1 and tau-ta...
制药公司规划穿越医药伦理雷区的路线图
制药公司规划穿越医药伦理雷区的路线图
重新定义CAR-T的速度与强度：与尼古拉斯·基里安探讨DAR-T™技术
重新定义CAR-T的速度与强度：与尼古拉斯·基里安探讨DAR-T™技术
伴随NIH经费削减而来的是患者安全与科学数据的风险
伴随NIH经费削减而来的是患者安全与科学数据的风险
制药业生产繁荣的四大启示
制药业生产繁荣的四大启示
礼来公司成为首家市值突破万亿美元的制药企业
The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that...
眼疾治疗管线下一步进展如何？
What’s next in the eye disease pipeline? An early gene therapy breakthrough spurred investments, but can the industry maintain momentum? Published Nov. 24, 2025 By Kell...
制药业将于2026年迎来酝酿多年的关键“转折点”
While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape.
大型制药公司员工如何评价他们的CEO？
There are many ways to steer the ship as the top exec of a large pharma company. Here are the ones employees approve of the most — as well as those who could polish the...
随着Madrigal面临MASH竞争对手，留住患者与寻找新患者同等重要。
Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.
Amylin有望在下一波减肥药浪潮中称雄。
With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.
制定癌症恶病质治疗路径
Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia.
阿尔茨海默病研发新突破即将到来，但非近在咫尺
While a couple drugs have reached the market, their effects are still modest, and experts say a true paradigm shift is still a ways off.
品牌目录带
把品牌目录放在视野里，但不抢主叙事
把工具、CRO、生物制药和器械公司做成滚动资源带，作为资讯流下方的辅助索引。
查看关于页 Thermo Fisher 核心工具与仪器
追踪 Danaher 核心工具与仪器
追踪 Agilent 核心工具与仪器
追踪 Merck KGaA 核心工具与仪器
追踪 Illumina 核心工具与仪器
追踪 Waters 核心工具与仪器
追踪 Bruker 核心工具与仪器
追踪 Sartorius 核心工具与仪器
追踪 Mettler Toledo 核心工具与仪器
追踪 PerkinElmer (Revvity) 核心工具与仪器
追踪 Bio-Rad 核心工具与仪器
追踪 Carl Zeiss 核心工具与仪器
追踪 Leica Microsystems 核心工具与仪器
追踪 Nikon 核心工具与仪器
追踪 Eppendorf 核心工具与仪器
追踪 Corning 核心工具与仪器
追踪 BD (Becton Dickinson) 核心工具与仪器
追踪 Beckman Coulter 核心工具与仪器
追踪 Qiagen 核心工具与仪器
追踪 Abcam 核心工具与仪器
追踪 MGI Tech (华大智造) 核心工具与仪器
追踪 Haier Biomedical 核心工具与仪器
追踪 Lonza 外包服务 (CRO / CDMO)
追踪 WuXi AppTec (药明康德) 外包服务 (CRO / CDMO)
追踪 WuXi Biologics 外包服务 (CRO / CDMO)
追踪 Charles River 外包服务 (CRO / CDMO)
追踪 Catalent 外包服务 (CRO / CDMO)
追踪 Samsung Biologics 外包服务 (CRO / CDMO)
追踪 IQVIA 外包服务 (CRO / CDMO)